An observational study in Alzheimer Disease, Inactivity and Preventive Therapy, sponsored by Technical University of Madrid. Recruiting at 1 site in Spain. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-17.
Sponsored by Technical University of Madrid · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.
Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 34th largest by planned enrollment of the 39 observational ones that give a count, is one of 20 that started in 2024, is one of 39 observational ones, reaches primary completion later than 10 of the 79 other live ones, and was the 247th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 55–85
Sanofi · Sites in Spain, United States, Australia and 4 more countries
Ages 55–85
Eidos Therapeutics, a BridgeBio company · Sites in Spain, United States, Singapore
Ages 18–80
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Spain, Australia, Austria and 14 more countries
Ages 18+
Exciva GmbH · Sites in Spain, United States, Canada and 6 more countries
Ages 55–90
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 81 · Phase 3 94 · Phase 4 4
First in 2002; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 258 across the 240 interventional studies, 400 across the 39 observational. Of the 187 that completed or were terminated, 91 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
178 of 279 have an industry lead sponsor. The 10 most frequent:
Technical University of Madrid is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
Technical University of Madrid has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
20 of the studies in Alzheimer Disease with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT07682155Germans Trias i Pujol HospitalStudy of the Brain's Natural Cleaning System in Potential Organ Donors. | 2026-11-30 |
| NCT07639645University of ValenciaIntervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 279 studies in Alzheimer Disease with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to investigate the cross-sectional relationship between physical activity and brain health from a multiscale approach (neuropsychology, neuroimaging, peripheral biomarkers and genetics) in former athletes and sedentary individuals. The main question it aims to answer is:
Do former athletes have better brain structure than sedentary people? Evaluating the differences in neurodegenerative processes between competitive training and sedentary and inactivity.
Region of Madrid
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Concentration of brain-derived neurotrophic factor (BDNF) in plasma (pg/mL)
Measured with ELISA kit (e.g., R\&D Systems, Cat. #DY248). Higher BDNF reflects greater neurotrophic support.
Time frame: Baseline
Concentration of total tau protein in plasma (pg/mL)
Assayed by high-sensitivity ELISA (e.g., Cusabio, Cat. #CSB-E13913h). Greater tau concentration indicates increased axonal injury or neurodegeneration.
Time frame: Baseline
Hippocampal volume measured by high-resolution 3 T T1-weighted MRI (mm³)
Volume extracted with FreeSurfer; Larger values indicate greater hippocampal integrity
Time frame: Baseline
Resting-state functional connectivity between primary motor cortex and supplementary motor area measured by 3 T fMRI (Fisher-Z)
Fisher-Z transformed correlation computed with CONN; Higher values indicate stronger connectivity
Time frame: Baseline
Digit Span Forward maximum span length (digits)
Attention assessed with Wechsler Adult Intelligence Scale-IV Digit Span Forward subtest; Maximum correctly repeated digit sequence recorded. Higher scores indicate better attention/short-term memory capacity.
Time frame: Baseline
Trail Making Test Part A completion time (seconds)
Visual attention and processing speed measured by TMT-A; time to connect 25 numbers in ascending order recorded. Shorter times indicate better performance.
Time frame: Baseline
Digit Span Backward maximum span length (digits)
Working memory measured with WAIS-IV Digit Span Backward; Longest correctly repeated backward sequence recorded. Higher scores indicate better working memory.
Time frame: Baseline
Trail Making Test Part B completion time (seconds)
Executive function (set-shifting) assessed by TMT-B; Time to alternately connect numbers and letters recorded. Shorter times indicate better executive control.
Time frame: Baseline
Verbal fluency (F-A-S) total words in 60 s (count)
Phonemic fluency tested with Controlled Oral Word Association Test (letters F, A, S, 60 s each); total correct words across three letters. Higher counts indicate better executive retrieval fluency.
Time frame: Baseline
Stroop Color-Word interference score (seconds)
Inhibition assessed with Golden Stroop test; The count of completions within 45 seconds is recorded. Lower times reflect better inhibitory control.
Time frame: Baseline
Montreal Cognitive Assessment (MoCA) total score (0 - 30 points)
10-minute screening of global cognition covering memory, attention, language, visuospatial, and executive domains. Values ≥ 26 are considered normal. Higher scores indicate better cognition.
Time frame: Baseline
Number of participants carrying at least one APOE ε4 allele (count of participants)
Genomic DNA isolated from EDTA whole blood; APOE genotyping by TaqMan SNP assays rs429358 and rs7412. Any ε4-containing genotype (ε2/ε4, ε3/ε4, ε4/ε4) classified as "ε4 carrier". Higher counts = higher ε4 prevalence.
Time frame: Baseline
Maximal oxygen uptake (VO₂max) measured by CPET with ramp protocol on treadmill (mL·kg-¹·min-¹)
Cardiopulmonary exercise test performed on treadmill using Ramp incremental ramp. Breath-by-breath gas exchange collected via metabolic cart. VO₂max defined as the highest 30-s average during the test; Higher values indicate better cardiorespiratory fitness.
Time frame: Baseline
Mean daily minutes of moderate-to-vigorous physical activity measured by ActiGraph wGT3X-BT accelerometer over 7 days (min/day)
Device worn on non-dominant wrist 24 h/day for 7 consecutive days. Raw data (100 Hz) processed in ActiLife with 10 s epochs; Freedson adult cut-points ≥ 1 952 counts·min-¹ define MVPA. Higher values indicate greater physical activity.
Time frame: Baseline
Body mass index (BMI) calculated from weight and stadiometer-measured height (kg/m²)
Height measured to 0.1 cm with height measuring rod. Weight obtained from InBody system. BMI = weight ÷ height². Higher BMI indicates greater overall adiposity.
Time frame: Baseline
Peak force of mid-thigh-pull test measured by portable force dynamometer (N)
Participants perform two maximal isometric mid-thigh pulls on calibrated dynamometer with 60 s rest. The higher of two trials recorded as peak force. Greater values indicate stronger lower-limb strength.
Time frame: Baseline
Handgrip strength measured by grip dynamometer (kg)
Standing posture, shoulder neutral, elbow extended. Two maximal squeezes per hand with dynamometer; 30 s rest between trials. Best value used for analysis. Higher values reflect greater grip strength.
Time frame: Baseline
Timed Up-and-Go (TUG) test completion time (seconds)
Participants stand up from a 45-cm chair, walk 3 m, turn, return, and sit; time recorded by timers. Two trials with 1 min rest; Shorter time retained. Lower times represent better agility.
Time frame: Baseline
Balance stability and speed score measured by TANITA force platform (unitless)
Balance and speed assessed on TANITA analyzer in eyes-open seated posture; Stand-up as fast as possible when signaled, repeat 3 times to get an optimal value; Manufacturer's composite stability index automatically computed (range 0-100). One 30-s trial; higher scores denote better balance.
Time frame: Baseline
Percentage body fat measured by multifrequency bioimpedance analyzer InBody system (%)
Participants barefoot, InBody 770 provides whole-body fat percentage derived from segmental impedance; Higher values denote greater adiposity.
Time frame: Baseline
Skeletal muscle mass measured by multifrequency bioimpedance analyzer InBody system (kg)
Analyzer outputs total skeletal muscle mass. Greater values indicate higher muscularity.
Time frame: Baseline
Waist circumference measured by flexible tape at midpoint between lowest rib and iliac crest (cm)
Measured at end-expiration; two readings within 1 cm averaged. Larger values indicate central adiposity.
Time frame: Baseline
Hip circumference measured by flexible tape at level of greater trochanters (cm)
Two readings averaged; used with waist girth to compute waist-to-hip ratio.
Time frame: Baseline
Serum triglycerides measured by enzymatic colorimetric assay (mg/dL)
Fasting venous blood; triglycerides quantified on chemistry analyzer with glycerol phosphate oxidase method. Higher values indicate greater dyslipidemia risk.
Time frame: Baseline
Serum total cholesterol measured by enzymatic colorimetric assay (mg/dL)
Chemistry analyzer; Cholesterol esterase/oxidase method. Higher levels indicate increased cardiovascular risk.
Time frame: Baseline
Serum high-density lipoprotein (HDL) cholesterol measured by enzymatic assay (mg/dL)
Selective detergent method. Higher HDL is considered protective.
Time frame: Baseline
Serum low-density lipoprotein (LDL) cholesterol calculated by Friedewald formula (mg/dL)
LDL-C = total-C - HDL-C - (triglycerides ÷ 5). Higher LDL indicates greater atherogenic risk.
Time frame: Baseline
Serum 25-hydroxyvitamin D concentration measured by chemiluminescent immunoassay (ng/mL)
Serum 25-hydroxyvitamin D concentration measured by chemiluminescent immunoassay (ng/mL)
Time frame: Baseline
Mean daily sedentary time measured by ActiGraph wGT3X-BT accelerometer over 7 days (min/day)
Sedentary time defined as \< 100 counts·min-¹ in vector-magnitudes; summed across valid waking wear days (≥ 10 h/day). Larger values denote more sedentary lifestyle.
Time frame: Baseline
Mean nightly sleep duration measured by ActiGraph wGT3X-BT over 7 nights (hours/night)
Sleep/wake scored with Cole-Kripke algorithm; average total sleep time across nights with ≥ 160 min valid sleep. Longer duration indicates better sleep quantity.
Time frame: Baseline
Total physical activity measured by International Physical Activity Questionnaire - Long Form (MET·min/week)
Four IPAQ domains are summed; for each activity, minutes are multiplied by the corresponding MET value and then summed. Higher values indicate greater total energy expenditure.
Time frame: Baseline
Mediterranean Diet Adherence Score measured by 14-item Mediterranean Diet Adherence Screener (0 - 14 points)
Each of the 14 items is scored 0 or 1 and summed (total 0-14). A score ≥ 9 is considered high adherence. Higher scores indicate greater adherence to the Mediterranean dietary pattern.
Time frame: Baseline
Plan to share: Undecided — At this stage, the investigators have not yet decided whether our IPD will be shared. Data sharing policies and procedures are still under discussion within our research group and institution. Further consideration will be given to ethical requirements, participant privacy, and potential future analyses before making a final decision.
Started Nov 2024 (actual). Primary completion is estimated for Jan 2026, 14 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Technical University of Madrid